So the Platform Comittee has endorsed the TPP

[cali]

36. The extension of drug patents will harm access to generic drugs

You don't find that problematic?

<snip>

The TPP also mandates that governments restrict competitor generic drug producers and regulatory authorities from using existing clinical data on biological medicines’ safety and efficacy, even in the absence of patents. That means that even when a medicine’s patent has expired, a drug company may continue to own the data that shows that it is effective and safe. This will compel generic drug producers seeking to produce generic drugs to undertake duplicative and unnecessary trials to re-prove findings that have already been scientifically demonstrated. In practice, the rules will deter generic drug companies from producing protected medicines, thereby extending the period before more affordable versions become available.

Pharmaceutical companies argue that monopoly protections need to be enhanced to spur research and development on life-saving drugs. However, drug companies already enjoy extensive monopoly benefits under existing intellectual property regimes, and a large amount of research into life-saving drugs is spurred not by profit motives but by government grants and tax incentives. In practice, the TPP’s intellectual property provisions will limit or undermine developing countries’ policy options for obtaining lower cost medicines, in particular those under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement. Once the TPP comes into force, public health systems, insurance providers, and patients will have to spend more to purchase life-saving drugs. In poorer countries, with limited health resources, patients who need life-saving or life-extending drugs may not receive them, resulting in those people dying or becoming sick earlier and more rapidly.

The TPP’s patent and other monopolistic protections for medicines cannot be justified on public health grounds. Not only are public health interests harmed by the TPP, those provisions may create the standards for future trade agreements and affect many more patients in the future.

<snip>

https://www.hrw.org/news/2016/01/12/qa-trans-pacific-partnership

This is a well respected site on copyright issues in general with many articles addressing Chapter 18

http://infojustice.org/archives/category/trade-agreements/trans-pacific-partnership